The metabolism of the synthetic cannabinoids ADB‐BUTINACA and ADB‐4en‐PINACA and their detection in forensic toxicology casework and infused papers seized in prisons
Open Access
- 22 November 2021
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (4) , 634-652
Abstract
Early warning systems detect new psychoactive substances (NPS), while dedicated monitoring programs and routine drug and toxicology testing identify fluctuations in prevalence. We report the increasing prevalence of the synthetic cannabinoid receptor agonist (SCRA) ADB‐BUTINACA (N‐[1‐amino‐3,3‐dimethyl‐1‐oxobutan‐2‐yl]‐1‐butyl‐1H‐indazole‐3‐carbox‐amide). ADB‐BUTINACA was first detected in a seizure in Sweden in 2019, and we report its detection in 13 routine Swedish forensic toxicology cases soon after. In January 2021, ADB‐BUTINACA was detected in SCRA‐infused papers seized in Scottish prisons and has rapidly increased in prevalence, being detected in 60.4% of the SCRA‐infused papers tested between January and July 2021. In this work, ADB‐BUTINACA was incubated with human hepatocytes (HHeps), and 21 metabolites were identified in vitro, 14 being detected in authentic case samples. The parent drug and metabolites B9 (mono‐hydroxylation on the n‐butyl tail) and B16 (mono‐hydroxylation on the indazole ring) are recommended biomarkers in blood, while metabolites B4 (dihydrodiol formation on the indazole core), B9, and B16 are suitable biomarkers in urine. ADB‐4en‐PINACA (N‐[1‐amino‐3,3‐dimethyl‐1‐oxobutan‐2‐yl]‐1‐[pent‐4‐en‐1‐yl]‐1H‐indazole‐3‐carboxamide) was detected in Scottish prisons in December 2020, but, unlike ADB‐BUTINACA, prevalence has remained low. ADB‐4en‐PINACA was incubated with HHeps, and 11 metabolites were identified. Metabolites E3 (dihydrodiol formed in the tail moiety) and E7 (hydroxylation on the linked/head group) are the most abundant metabolites in vitro and are suggested as urinary biomarkers. The in vitro potencies of ADB‐BUTINACA (EC50, 11.5 nM and ADB‐4en‐PINACA (EC50, 11.6 nM) are similar to that of MDMB‐4en‐PINACA (EC50, 4.3 nM). A third tert‐leucinamide SCRA, ADB‐HEXINACA was also detected in prison samples and warrants further investigation.Keywords
Funding Information
- Linköpings Universitet (Strategic Research Area in Forensic Sciences)
- Leverhulme Trust (RC‐2015‐01)
- Linköpings Universitet
- VINNOVA (2019‐03566)
- European Commission (E! 113377 (Eurostars‐2))
This publication has 38 references indexed in Scilit:
- In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic CannabinoidCurrent Neuropharmacology, 2017
- Adding Spice to the Porridge11‘Porridge’ is British slang for a prison sentence. E.g. ‘Doing his porridge’. The term is most commonly thought to be an allusion to the fact that porridge is, or used to be, a common food in prison. The term is also thought to be a pun on the much older slang word for prison, ‘stir’.: The development of a synthetic cannabinoid market in an English prisonInternational Journal of Drug Policy, 2017
- From niche to stigma—Headshops to prison: Exploring the rise and fall of synthetic cannabinoid use among young adultsInternational Journal of Drug Policy, 2017
- Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker MetabolitesClinical Pharmacology & Therapeutics, 2016
- High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human HepatocytesClinical Chemistry, 2016
- Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substancesForensic Toxicology, 2015
- Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometryForensic Toxicology, 2015
- Liquid chromatography/time-of-flight mass spectrometry analysis of postmortem blood samples for targeted toxicological screeningAnalytical and Bioanalytical Chemistry, 2013
- International Union of Pharmacology. XXVII. Classification of Cannabinoid ReceptorsPharmacological Reviews, 2002
- Pharmacology of cannabinoid CB1 and CB2 receptorsPharmacology & Therapeutics, 1997